Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1637 1642 1643 1644
This examiner grants 74% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18248189 | MOTIF NEOEPITOPES FOR CANCER IMMUNOTHERAPY | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17773283 | DEGRADATION OF SURFACE PROTEINS USING BISPECIFIC BINDING AGENT | Final Rejection | The Regents of the University of California |
| 18032012 | SYNTHETIC ANTIGENS AS CHIMERIC ANTIGEN RECEPTOR (CAR) LIGANDS AND USES THEREOF | Non-Final OA | Georgia Tech Research Corporation |
| 18066529 | PROTEASE-ACTIVATED T CELL BISPECIFIC ANTIBODIES | Non-Final OA | Hoffmann-La Roche Inc. |
| 18034026 | METHODS OF TREATING INFECTIONS BY BLOCKING PATHOGEN MIMICS OF CD47 | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17927529 | BISPECIFIC MOLECULES FOR SELECTIVELY MODULATING T CELLS | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 18252928 | ANTI-CD6 ANTIBODY CONJUGATES FOR TREATING T-CELL MEDIATED DISORDERS AND T-CELL LYMPHOMA/LEUKEMIA | Non-Final OA | The Cleveland Clinic Foundation |
| 16970930 | UNIVERSAL ANTIGEN PRESENTING CELLS AND USES THEREOF | Non-Final OA | Board of Regents, The University of Texas System |
| 18326335 | ANTI-BMP9 ANTIBODIES AND METHODS OF USE THEREOF | Non-Final OA | The General Hospital Corporation |
| 18008278 | Improved T cell receptor-costimulatory molecule chimera | Non-Final OA | TSINGHUA UNIVERSITY |
| 18010910 | UNIVERSAL CAR-NK CELL TARGETING VARIOUS EPITOPES OF HIV-1 GP160 | Non-Final OA | University of Southern California |
| 17765585 | METHODS AND COMBINATIONS FOR THE TREATMENT OF CANCER USING IMMUNE CHECKPOINT INHIBITOR ANTIBODIES | Non-Final OA | ASTRAZENECA AB |
| 18007290 | METHODS TO STIMULATE IMMUNE RESPONSES TO MUTANT RAS USING ANUCLEATE CELLS | Non-Final OA | STEMCELL TECHNOLOGIES CANADA INC. |
| 17997161 | TREATMENT AND PREVENTION OF CANCER USING VIRUS-SPECIFIC IMMUNE CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS | Final Rejection | Baylor College of Medicine |
| 17755278 | INTRATUMORAL ADMINISTRATION OF IMMUNE CELLULAR THERAPEUTICS | Final Rejection | FIGENE, LLC |
| 17630601 | METHODS FOR TREATMENT OF REFRACTORY GENERALIZED MYASTHENIA GRAVIS WITH ECULIZUMAB | Final Rejection | Alexion Pharmaceuticals, Inc. |
| 17830865 | PLACENTA-DERIVED ALLOGENEIC CAR-T CELLS AND USES THEREOF | Final Rejection | Sorrento Therapeutics, Inc. |
| 18285636 | CHIMERIC ANTIGEN RECEPTOR COMPRISING AN ANTI-HER2 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND NATURAL KILLER CELLS COMPRISING THE SAME | Non-Final OA | GC CELL CORPORATION |
| 18285634 | CHIMERIC ANTIGEN RECEPTOR COMPRISING AN ANTI-CD19 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND NATURAL KILLER CELLS COMPRISING THE SAME | Non-Final OA | GC Cell Corporation |
| 17777659 | STIMULI THAT HYPERACTIVATE RESIDENT DENDRITIC CELLS FOR CANCER IMMUNOTHERAPY | Non-Final OA | Children's Medical Center Corporation |
| 18272329 | COMPOSITIONS AND METHODS FOR PREVENTING TUMORS AND CANCER | Non-Final OA | Cancer Advances Inc. |
| 18256172 | ANTIBODY SPECIFIC FOR CD47 AND USES THEREOF | Non-Final OA | INNOBATION BIO., LTD. |
| 18299204 | COMPOSITION FOR ANTIVIRUS COMPRISING NATURAL KILLER CELL | Non-Final OA | NOVOCELL Bio Co., Ltd. |
| 18113399 | ACTIVATABLE IL-18 POLYPEPTIDES | Final Rejection | Bright Peak Therapeutics AG |
| 18160886 | ANTI-PVRIG PROTEIN ANTIBODY OR ANTIBODY FRAGMENT AND USE THEREOF | Non-Final OA | HEFEI TG IMMUNOPHARMA CO., LTD. |
| 18056410 | ENGINEERED PD-1 ANTIBODIES AND USES THEREOF | Non-Final OA | MiroBio Limited |
| 17926790 | FUSION PROTEIN FOR REVERSING TUMOR MICROENVIRONMENT AND USE THEREOF | Non-Final OA | CHONGQING PRECISION BIOLOGICAL INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE CO., LTD. |
| 17916503 | COMBINATION THERAPY INVOLVING ANTI-CD39 ANTIBODIES AND ADOPTIVE CELL THERAPY | Non-Final OA | Trishula Therapeutics, Inc. |
| 17789079 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES AND CANCERS BY TARGETING IGSF8 | Non-Final OA | GV20 Therapeutics LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy